This content is machine translated Oral JAK-i in atopic dermatitis Benefits and risks: What does the current data say? Although there have been no recent approvals of oral JAK inhibitors (JAK-i) for atopic dermatitis (AD), some interesting study findings have been published. These shed light on the safety of...…
This content is machine translated Rheumatoid arthritis in elderly patients Evidence-based therapy selection under the aspect of benefits and risks Current evidence suggests that the benefits of low-dose steroid therapy are greater than the harms in elderly patients with rheumatoid arthritis (RA). This is evident from the GLORIA study, in…
